Overview
Today’s scanner produced 24 Continuation Breakout signals against a backdrop the WaveRider SA Regime engine classifies as Correction, with breadth sitting at just 18.3% above the SMA-40 and sentiment reading Bearish/Oversold. In this kind of tape, continuation setups can still work, but the market is not rewarding aggression — leadership is narrow and confined to defensive/growth pockets rather than broad participation.
Sector-wise, Health Care (2.1% ATR%) and Technology (1.5% ATR%) are the only groups showing relative strength, while Financials, Real Estate, and Utilities are bleeding volatility to the downside. Of today’s top candidates, five are Medical/Biotech names, two are Semiconductor Equipment plays, and the remainder are scattered across Software, Computer Hardware, and Retail — a moderate concentration in the leading Health Care theme, which is constructive given the regime.
Given the Correction backdrop, quality scores are capped at 3/5 across the board per our regime adjustment rules. RVOL readings were mixed — several names (STX, FTNT, KLAC) actually printed below-average volume (0.6–0.9x), which is a yellow flag for continuation validity, while AGEN’s 3.0x RVOL stands out as the most volume-confirmed move of the day. Institutional backing is strong across the medical names (DHR: 3,669 funds, KLAC: 4,387 funds, STX: 3,633 funds), giving some confidence in underlying sponsorship even as price action stays choppy.
Top 5 Picks
DHR ($227.33) — Medical / Research
Danaher is sitting right at a daily demand zone (219.92–221.56, strength 6.8) with RVOL of 1.2 and a healthy ATR%-M of 4.0, indicating the stock has room to extend. Heavy institutional presence (3,669 funds) supports a continuation thesis toward the weekly supply zone above.
| Entry | Stop | Target |
|---|---|---|
| $227.33 | $219.50 (-3.4%) | $233.49 / $242.80 (+2.7% / +6.8%) |
Institutional Backing: 3,669 funds tracked, no specific bucket flag — broad institutional coverage.
BIIB ($228.69) — Medical / Profitable Biotech
Biogen is holding a tight 30-minute demand shelf (226.34–226.53, strength 6.7) with RVOL 1.4 and ATR%-M of 2.9 — a clean continuation structure just 0.8% off the 52-week high. Weekly supply near 241–246 offers a well-defined upside target.
| Entry | Stop | Target |
|---|---|---|
| $228.69 | $225.50 (-1.4%) | $240.98 / $246.44 (+5.4% / +7.7%) |
Institutional Backing: 2,458 funds tracked.
FTNT ($176.33) — Software / Security
Fortinet is pressing a 1-hour demand zone (172.28–173.13) in a Technology sector that’s showing relative leadership (1.5% ATR%). RVOL is soft at 0.6, so this is more of a patient add-on setup than a momentum chase, but strength readings (5.4/5.3) on both sides of the zone suggest a coiled range ready to resolve higher.
| Entry | Stop | Target |
|---|---|---|
| $176.33 | $172.00 (-2.5%) | $180.91 (+2.6%) |
Institutional Backing: 3,322 funds, Bucket B2.
TARS ($76.81) — Medical / Revenue Biotech
Tarsus Pharmaceuticals is squeezed between a 4-hour demand zone (74.22–75.96) and a daily supply zone just 0.35% overhead (77.08–78.59) — a classic tight-range continuation coil. RVOL of 1.2 and ATR%-M of 2.1 support a breakout attempt through the nearby supply.
| Entry | Stop | Target |
|---|---|---|
| $76.81 | $74.00 (-3.7%) | $78.59 (+2.3%) |
Institutional Backing: 391 funds, Bucket B0/B1 — smaller-cap coverage.
WAT ($442.94) — Medical / Systems
Waters Corp is just 0.6% off its 52-week high with RVOL 1.5 and a strong ATR%-M of 3.4, showing this is one of the more volume-confirmed setups in today’s scan. Deep institutional ownership (2,526 funds) adds conviction to a breakout attempt to fresh highs.
| Entry | Stop | Target |
|---|---|---|
| $442.94 | $430.00 (-2.9%) | $455.00 (+2.7%, new 52W high extension) |
Institutional Backing: 2,526 funds, Bucket B1.
Honorable Mentions
- ASML ($1771.41) — Semiconductor equipment leader consolidating between demand (1696–1711) and weekly supply (1894–1942), worth watching on volume expansion.
- KLAC ($189.17) — Sitting at supply (191.4–195.9) with near-zero ATR%-M (0.1); wait for a pullback rather than chasing here.
- STX ($921.51) — At supply just 0.87% away with soft RVOL (0.9); the risk/reward favors patience over immediate entry.
- AGEN ($9.43) — Highest RVOL of the day (3.0) and +10.4% move, but thin institutional base (92 funds) makes this a speculative, high-volatility play only.
- BURL ($266.39) — +4.6% move on 1.2x RVOL, but negative ATR%-M (-3.5%) signals fading momentum despite the price pop.
Strategy Summary
Today’s setup quality is capped at a 3 out of 5 given the Correction regime — traders should favor confirmation over anticipation and size positions conservatively. The clear theme is Health Care/Medical strength (DHR, BIIB, WAT, TARS all in-zone at demand) complemented by selective Technology exposure (FTNT), aligning with the two sectors actually showing positive relative ATR% today. Avoid chasing names sitting at supply (STX, KLAC) in this tape — the better risk/reward lies in demand-zone continuation plays with tight stops and modest 3-7% target ranges. Overall, this is a stock-picker’s day, not a broad-based breakout environment.